An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany.

ABSTRACT:

Background

This study aimed to evaluate cost-utility of baroreflex activation therapy (BAT) using the Barostim neo™ device (CVRx Inc., Minneapolis, MN, USA) compared with optimized medical management in patients with advanced chronic heart failure (NYHA class III) who were not eligible for treatment with cardiac resynchronization therapy, from a statutory health insurance perspective in Germany over a lifetime horizon.

Methods

A decision analytic model was developed using the combination of a decision tree and the Markov process. The model included transitions between New York Heart Association (NYHA) health states, each of which is associated with a risk of mortality, hospitalization, cost, and quality of life. The effectiveness of BAT was projected through relative risks f

SUBMITTER: Borisenko O 

PROVIDER: S-EPMC6085633 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature